- Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEFQiu, Mei*; Ding, Liang-Liang; Zhan, Ze-Lin; Zhou, Hai-RongESC Heart Failure, 2021, 8(2): 1722-1724.被引 2
- Does Combination Therapy With SGLT2 Inhibitors and Renin-Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?Zhao, Li-Min; Zhang, Miao; Zhan, Ze-Lin; Qiu, Mei*Frontiers in Cardiovascular Medicine, 2021, 8: 679124.被引 5
- The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failureHeerspink, J. L.; Wheeler, D. C.; Vart, P.; Jongs, N.; Hou, F. F.; Langkilde, A. M.; Correa-Rotter, R.; Rossing, P.; Sjostrom, C. D.; Toto, R. D.; Chertow, G. M.; Stefansson, B. V.; McMurray, J. J. V.
期刊论文
Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
3被引8阅读
